Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia
Abstract
:1. Introduction
2. Results
Case Report
3. Discussion
4. Conclusions
5. Future Perspective
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Darwiche, W.; Gubler, B.; Marolleau, J.P.; Ghamlouch, H. Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues from a Functional Perspective. Front. Immunol. 2018, 9, 683. [Google Scholar] [CrossRef] [PubMed]
- Seifert, M.; Sellmann, L.; Bloehdorn, J.; Wein, F.; Stilgenbauer, S.; Dürig, J.; Küppers, R. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J. Exp. Med. 2012, 209, 2183–2198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hamblin, T.J.; Davis, Z.; Gardiner, A.; Oscier, D.G.; Stevenson, F.K. Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94, 1848–1854. [Google Scholar] [CrossRef] [PubMed]
- Morrison, V.A. Infectious Complications of Chronic Lymphocytic Leukaemia: Pathogenesis, Spectrum of Infection, Preventive Approaches. Best Pract. Res. Clin. Haematol. 2010, 23, 145–153. [Google Scholar] [CrossRef] [PubMed]
- Dearden, C. Disease-specific complications of chronic lymphocytic leukemia. Hematol. Am. Soc Hematol. Educ. Program. 2008, 1, 450–456. [Google Scholar] [CrossRef] [Green Version]
- Maffei, R.; Bulgarelli, J.; Fiorcari, S.; Bertoncelli, L.; Martinelli, S.; Guarnotta, C.; Castelli, I.; Deaglio, S.; Debbia, G.; De Biasi, S.; et al. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 2013, 98, 1115–1123. [Google Scholar] [CrossRef]
- Burger, J.A.; Gribben, J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new-targeted therapies. Semin Cancer Biol. 2014, 24, 71–81. [Google Scholar] [CrossRef]
- Audrito, V.; Serra, S.; Brusa, D.; Mazzola, F.; Arruga, F.; Vaisitti, T.; Coscia, M.; Maffei, R.; Rossi, D.; Wang, T.; et al. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood 2015, 125, 111–123. [Google Scholar] [CrossRef]
- DiLillo, D.J.; Weinberg, J.B.; Yoshizaki, A.; Horikawa, M.; Bryant, J.M.; Iwata, Y.; Matsushita, T.; Matta, K.M.; Chen, Y.; Venturi, G.M.; et al. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013, 27, 170–182. [Google Scholar] [CrossRef] [Green Version]
- Chiorazzi, N.; Fu, S.M.; Montazeri, G.; Kunkel, H.G.; Rai, K.; Gee, T. T cell helper defect in patients with chronic lymphocytic leukemia. J. Immunol. 1979, 122, 1087–1090. [Google Scholar]
- Riches, J.C.; Gribben, J.G. Immunomodulation and immune reconstitution in chronic lymphocytic leukemia. Semin. Hematol. 2014, 51, 228–234. [Google Scholar] [CrossRef] [PubMed]
- Mauri, C.; Bosma, A. Immune regulatory function of B cells. Annu. Rev. Immunol. 2012, 30, 221–241. [Google Scholar] [CrossRef] [PubMed]
- Scheffold, A.; Stilgenbauer, S. Revolution of Chronic Lymphocytic Leukemia Therapy: The Chemo-Free Treatment Paradigm. Curr. Oncol. Rep. 2020, 22, 16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seymour, E.K. Rapid Transitions in the Standard of Care for Chronic Lymphocytic Leukemia (CLL). Oncotarget 2019, 10, 2484–2485. [Google Scholar] [CrossRef]
- Long, M.; Beckwith, K.; Do, P.; Mundy, B.L.; Gordon, A.; Lehman, A.M.; Maddocks, K.J.; Cheney, C.; Jones, J.A.; Flynn, J.M.; et al. Ibrutinib treatment improves T cell number and function in CLL patients. J. Clin. Investig. 2017, 127, 3052–3064. [Google Scholar] [CrossRef]
- Juárez-Salcedo, L.M.; Desai, V.; Dalia, S. Venetoclax: Evidence to date and clinical potential. Drugs Context 2019, 8, 212574. [Google Scholar] [CrossRef]
- Furman, R.R.; Sharman, J.P.; Coutre, S.E.; Cheson, B.D.; Pagel, J.M.; Hillmen, P.; Barrientos, J.C.; Zelenetz, A.D.; Kipps, T.J.; Flinn, I.; et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014, 370, 997–1007. [Google Scholar] [CrossRef] [Green Version]
- Fürstenau, M.; De Silva, N.; Eichhorst, B.; Hallek, M. Minimal Residual Disease Assessment in CLL: Ready for Use in Clinical Routine? Hemasphere 2019, 3, e287. [Google Scholar] [CrossRef]
- Hofland, T.; Eldering, E.; Kater, A.P.; Tonino, S.H. Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia. Int. J. Mol. Sci. 2019, 20, 4315. [Google Scholar] [CrossRef] [Green Version]
- Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of Natural Killer Cells. Nat. Immunol. 2008, 9, 503–510. [Google Scholar] [CrossRef]
- Stabile, H.; Fionda, C.; Gismondi, A.; Santoni, A. Role of Distinct Natural Killer Cell Subsets in Anticancer Response. Front. Immunol. 2017, 8, 293. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Poli, A.; Michel, T.; Thérésine, M.; Andrès, E.; Hentges, F.; Zimmer, J. CD56bright natural killer (NK) cells: An important NK cell subset. Immunology 2009, 126, 458–465. [Google Scholar] [CrossRef] [PubMed]
- Jewett, A.; Kos, J.; Kaur, K.; Safaei, T.; Sutanto, C.; Chen, W.; Wong, P.; Namagerdi, A.K.; Fang, C.; Fong, Y.; et al. Natural Killer Cells: Diverse Functions in Tumor Immunity and Defects in Pre-neoplastic and Neoplastic Stages of Tumorigenesis. Mol. Ther. Oncolytics 2019, 16, 41–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, T.K.; Caudell, E.G.; Smid, C.; Grimm, E.A. IL-2 Activation of NK Cells: Involvement of MKK1/2/ERK but Not P38 Kinase Pathway. J. Immunol. 2000, 164, 6244–6251. [Google Scholar] [CrossRef] [Green Version]
- Fehniger, T.A.; Bluman, E.M.; Porter, M.M.; Mrózek, E.; Cooper, M.A.; VanDeusen, J.B.; Frankel, S.R.; Stock, W.; Caligiuri, M.A. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J. Clin. Investig. 2000, 106, 117–124. [Google Scholar] [CrossRef] [Green Version]
- Maharaj, D.; Vianna, P.; DeCarvalho, G.; Pourkalbassi, D.; Hickey, C.; Gouvea, J. Molecular Remission Using Low-Dose Immunotherapy for Relapsed Refractory Philadelphia Chromosome-Positive Precursor B-Cell Acute Lymphoblastic Leukemia Post-Allogeneic Stem Cell Transplant. Future Sci. OA 2019, 5, FSO380. [Google Scholar] [CrossRef] [Green Version]
- Ramsay, A.G.; Clear, A.J.; Fatah, R.; Gribben, J.G. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: Establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120, 1412–1421. [Google Scholar] [CrossRef]
- Ramsay, A.G.; Evans, R.; Kiaii, S.; Svensson, L.; Hogg, N.; Gribben, J.G. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121, 2704–2714. [Google Scholar] [CrossRef]
- Pittari, G.; Vago, L.; Festuccia, M.; Bonini, C.; Mudawi, D.; Giaccone, L.; Bruno, B. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Front. Immunol. 2017, 8, 1444. [Google Scholar] [CrossRef] [Green Version]
- Anderson, M.A.; Deng, J.; Seymour, J.F.; Tam, C.; Kim, S.Y.; Fein, J.; Yu, L.; Brown, J.R.; Westerman, D.; Si, E.G.; et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016, 127, 3215–3224. [Google Scholar] [CrossRef] [Green Version]
- Kaur, K.; Topchyan, P.; Kozlowska, A.K.; Ohanian, N.; Chiang, J.; Maung, P.O.; Park, S.-H.; Ko, M.-W.; Fang, C.; Nishimura, I.; et al. Super-Charged NK Cells Inhibit Growth and Progression of Stem-like/Poorly Differentiated Oral Tumors in Vivo in Humanized BLT Mice; Effect on Tumor Differentiation and Response to Chemotherapeutic Drugs. Oncoimmunology 2018, 7, e1426518. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Choudhry, H.; Helmi, N.; Abdulaal, W.H.; Zeyadi, M.; Zamzami, M.A.; Wu, W.; Mahmoud, M.M.; Warsi, M.K.; Rasool, M.; Jamal, M.S. Prospects of IL-2 in Cancer Immunotherapy. BioMed Res. Int. 2018, 2018, 9056173. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Darabi, K.; Kantamnei, S.; Wiernik, P.H. Lenalidomide-induced warm autoimmune hemolytic anemia. J. Clin. Oncol. 2006, 24, e59. [Google Scholar] [CrossRef] [PubMed]
- De Weerdt, I.; Hofland, T.; de Boer, R.; Dobber, J.A.; Dubois, J.; van Nieuwenhuize, D.; Mobasher, M.; de Boer, F.; Hoogendoorn, M.; Velders, G.A.; et al. Distinct Immune Composition in Lymph Node and Peripheral Blood of CLL Patients Is Reshaped during Venetoclax Treatment. Blood Adv. 2019, 3, 2642–2652. [Google Scholar] [CrossRef] [PubMed]
- Seymour, J.F.; Davids, M.S.; Roberts, A.W.; Hallek, M.; Wierda, W.G.; Hillmen, P.; Gerecitano, J.F.; Cerri, E.; Potluri, J.; Kim, S.Y.; et al. Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia. Blood 2016, 128, 4395. [Google Scholar] [CrossRef]
- He, X.S.; Draghi, M.; Mahmood, K.; Holmes, T.H.; Kemble, G.W.; Dekker, C.L.; Arvin, A.M.; Parham, P.; Greenberg, H.B. T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J. Clin. Investig. 2004, 114, 1812–1819. [Google Scholar] [CrossRef]
- Crombie, J.; Davids, M.S. IGHV mutational status testing in chronic lymphocytic leukemia. Am. J. Hematol. 2017, 92, 1393–1397. [Google Scholar] [CrossRef] [Green Version]
- Friedman, D.R.; Sibley, A.B.; Owzar, K.; Chaffee, K.G.; Slager, S.; Kay, N.E.; Hanson, C.A.; Ding, W.; Shanafelt, T.D.; Weinberg, J.B.; et al. Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: A multi-institutional study. Am. J. Hematol. 2016, 91, 687–691. [Google Scholar] [CrossRef] [Green Version]
- Alhakeem, S.S.; McKenna, M.K.; Oben, K.Z.; Noothi, S.K.; Rivas, J.R.; Hildebrandt, G.C.; Fleischman, R.A.; Rangnekar, V.M.; Muthusamy, N.; Bondada, S. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity. J. Immunol. 2018, 200, 4180–4189. [Google Scholar] [CrossRef]
Date of Visit | FISH 13q14.3 (Normal < 3.1%) | Absolute Number of Abnormal CLL Cells * K/μL | Detected Abnormalities |
---|---|---|---|
31 January 2017 | 71% | 9.27 (59%) | ZAP-70 positive Unmutated IGHV: 0.3% |
7 April 2017 | 52% | 1.91 (49%) | ZAP-70 positive SF3B1 mutation: detected TP53 deletion: not detected NOTCH1: not detected Unmutated IGHV: 1.7% |
8 June 2017 | 51% | 0.27 (16%) | ZAP-70 positive SF3B1 mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Unmutated IGHV: 1.0% |
4 August 2017 | 26% | 0.13 (9%) | SF3B1 mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Mutated IGHV: 6.0% |
18 October 2017 | Not detected | 0.11 (10%) | SF3B1 mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Mutated IGHV: 9.5% |
27 March 2018 | 24% | 0.08 (5%) | SF3B1 mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Unmutated IGHV: 0.34% |
5 June 2018 | 21% | 0.62 (27%) | Unmutated IGHV: 0% |
17 May 2019 | 93% | 49.6 (79%) | SF3B1 mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Unmutated IGHV: 0.3% |
26 August 2019 | 52% | 0.33 (55%) | SF3B1 mutation: detected ATM mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Unmutated IGHV: 0% |
3 October 2019 | 7.5% | 0.33 (9.6%) | SF3B1 mutation: detected ATM mutation: detected TP53 mutation: not detected NOTCH1: not detected MYD88: not detected Mutated IGHV: 12.8% |
6 December 2019 | Not detected | No abnormal CLL cells (0%) | No mutations |
12 March 2020 | Not detected | No abnormal CLL cells (0%) | No mutations |
29 September 2020 | Not detected | No abnormal CLL cells (0%) | No mutations |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Maharaj, D.; Srinivasan, G.; Abreu, M.M.; Ko, M.-W.; Jewett, A.; Gouvea, J. Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia. Cells 2021, 10, 10. https://doi.org/10.3390/cells10010010
Maharaj D, Srinivasan G, Abreu MM, Ko M-W, Jewett A, Gouvea J. Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia. Cells. 2021; 10(1):10. https://doi.org/10.3390/cells10010010
Chicago/Turabian StyleMaharaj, Dipnarine, Gayathri Srinivasan, Maria M. Abreu, Meng-Wei Ko, Anahid Jewett, and Jacqueline Gouvea. 2021. "Molecular Remission Using Low-Dose Immunotherapy with Minimal Toxicities for Poor Prognosis IGHV—Unmutated Chronic Lymphocytic Leukemia" Cells 10, no. 1: 10. https://doi.org/10.3390/cells10010010